Anthera Pharmaceuticals, Inc.
Other OTCTotal Valuation
Anthera Pharmaceuticals, Inc. carries a market capitalization of 2,618.00, placing it among publicly traded companies globally. Its enterprise value stands at -3.58M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 2,618.00 |
| Enterprise Value | -3.58M |
Share Statistics
Anthera Pharmaceuticals, Inc. currently has 26.18M shares outstanding.
| Shares Outstanding | 26.18M |
| Owned by Insiders (%) | N/A |
| Owned by Institutions (%) | N/A |
Valuation Ratios
| PE Ratio | N/A |
| PS Ratio | N/A |
| PB Ratio | -0.01 |
| P/TBV Ratio | 0.83 |
| P/FCF Ratio | -0.14 |
| P/OCF Ratio | -0.14 |
Financial Position
Anthera Pharmaceuticals, Inc. maintains a current ratio of 3.30, meaning it holds 3.3x the short-term assets needed to cover near-term liabilities.
| Current Ratio | 3.30 |
| Quick Ratio | 3.06 |
| Debt / Equity | N/A |
| Debt / EBITDA | N/A |
| Interest Coverage | N/A |
Financial Efficiency
| Return on Equity (ROE) | N/A |
| Return on Assets (ROA) | -144.38 |
| Return on Invested Capital (ROIC) | N/A |
| Return on Capital Employed (ROCE) | 10.14 |
| Revenue Per Employee | N/A |
| Employee Count | N/A |
| Inventory Turnover | N/A |
Stock Price Statistics
Anthera Pharmaceuticals, Inc.'s stock has gained approximately 0.000003% over the past 52 weeks. The 50-day moving average sits at 0.00, while the 200-day moving average is 0.00.
| Beta (5Y) | N/A |
| 52-Week Price Change | 0.000003% |
| 50-Day Moving Average | 0.00 |
| 200-Day Moving Average | 0.00 |
| Average Volume (20 Days) | N/A |
Income Statement
EBITDA reached -36.30M, while operating income came in at -36.70M.
| Revenue | N/A |
| Gross Profit | N/A |
| Operating Income | -36.70M |
| Pretax Income | -23.39M |
| Net Income | -23.39M |
| EBITDA | -36.30M |
| EBIT | -36.70M |
| Earnings Per Share (EPS) | -1.66 |
Balance Sheet
Total book value stands at -442.13M, with working capital of 6.09M providing operational flexibility.
| Cash & Cash Equivalents | 8.09M |
| Total Debt | N/A |
| Net Debt | -8.09M |
| Equity (Book Value) | -442.13M |
| Book Value Per Share | -31.33 |
| Working Capital | 6.09M |
Cash Flow
Anthera Pharmaceuticals, Inc. produced -31.95M in operating cash flow over the past twelve months.
| Operating Cash Flow | -31.95M |
| Capital Expenditures | N/A |
| Free Cash Flow | -31.95M |
| FCF Per Share | -2.26 |
Dividends & Yields
The company's payout ratio of 6.18 indicates the proportion of earnings distributed to shareholders.
| Dividend Per Share | N/A |
| Dividend Yield | N/A |
| Payout Ratio | 6.18 |
| Shareholder Yield | -422.20 |
| FCF Yield | -708.97 |
Stock Splits
Anthera Pharmaceuticals, Inc.'s most recent stock split took place on May 1, 2017 with a 8:1 split ratio.
| Last Split Date | 5/1/2017 |
| Split Ratio | 8:1 |
Scores
Anthera Pharmaceuticals, Inc. posts an Altman Z-Score of -82.36, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | -82.36 |